Daraxonrasib Earns EMA Positive Opinion in Pretreated Metastatic PDAC: First-Mover Advantage Under Competitive Siege

EMA Recommends Six New Medicines, Including Rasonque for Pancreatic Cancer

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) concluded its October 2026 meeting by recommending six new medicines for approval. Among these, Rasonque (daraxonrasib) received a positive opinion for the treatment of adults with metastatic pancreatic adenocarcinoma who have undergone at least one prior treatment. This recommendation for Rasonque was a high-priority outcome under EMA’s Cancer Medicines Pathfinder project, addressing a significant unmet medical need. Other new medicines recommended include Foundayo (orforglipron) for weight management and type 2 diabetes, Yuviwel (navepegritide) for achondroplasia, and two biosimilars. Additionally, the CHMP recommended extensions of therapeutic indications for five existing medicines.

• Rasonque (daraxonrasib) secured a positive opinion from the CHMP for marketing authorization, specifically targeting adults with metastatic pancreatic adenocarcinoma. This approval is significant for patients who have already undergone at least one prior treatment, addressing a critical unmet medical need in a challenging cancer type. The phased review process under the EMA’s Cancer Medicines Pathfinder project underscores the drug's high-priority status and its potential to offer a new therapeutic option.
• The CHMP's October 2026 meeting was productive, recommending a total of six new medicines for approval. Beyond Rasonque, these included Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and type 2 diabetes, Yuviwel (navepegritide) for achondroplasia in children, and two biosimilar medicines, Fovlussea (ranibizumab) and Neuzafy (filgrastim). This broad range of recommendations reflects the EMA's ongoing efforts to bring diverse new treatments to the European market across various therapeutic areas.
• In addition to new approvals, the CHMP also recommended extensions of therapeutic indications for five already-authorized medicines, including Pandemic influenza vaccine H5N1 AstraZeneca, Kyinsu, Talvey, Tryngolza, and Tukysa. Conversely, the committee confirmed its refusal for Yartemlea (narsoplimab)'s marketing authorization after re-examination and noted the withdrawal of applications for Ibrance (palbociclib) and Truqap (capivasertib) for extended uses, indicating a rigorous and comprehensive regulatory review process.

Addressing Unmet Needs in Metastatic Pancreatic Adenocarcinoma

Despite incremental advances in first-line chemotherapy, metastatic pancreatic adenocarcinoma (mPDAC) continues to carry a poor prognosis with limited therapeutic options across the disease continuum. Recent literature highlights several distinct unmet needs and patient populations where current standard-of-care regimens fall short, driving a wave of clinical investigation into novel combinations and molecularly defined subgroups.

• Second-line and later-line treatment after FOLFIRINOX progression. Selecting effective therapy following first-line FOLFIRINOX remains a major clinical challenge. A large multicenter retrospective analysis of 160 Italian mPC patients treated with nab-paclitaxel/gemcitabine (AG) as second or later-line therapy reported a median PFS of 3.9 months and median OS of 6.8 months overall; in the 76 patients receiving AG after first-line FOLFIRINOX, median PFS was 3.5 months and median OS was 5.7 months, with an ORR of 19.7% and DCR of 46.0%. Independent prognostic factors identified at multivariate level — including LDH, NLR, fasting serum glucose, liver metastases, ECOG PS, and first-line PFS — were used to construct a prognostic nomogram to stratify second-line risk, underscoring the need for better patient selection tools in this setting.

• Optimising first-line regimen sequencing and combination strategies. The relative merits of available first-line backbones remain an active area of investigation. A systematic review and meta-analysis across 7 phase 3 trials (2,581 patients) found that NALIRIFOX and FOLFIRINOX were associated with similar PFS (7.4 and 7.3 months, respectively) and OS (11.1 and 11.7 months, respectively), both superior to GEM-NABP (PFS 5.7 months; OS 10.4 months), yet with distinct toxicity profiles — highlighting that no single regimen satisfies all patient profiles. Separately, the ongoing GABRINOX-2 phase II randomised trial is evaluating sequential GEMBRAX followed by FOLFIRINOX versus FOLFIRINOX alone in mPC, with circulating tumour DNA and mRNA signature analyses embedded to identify predictive biomarkers.

• Immunologically "cold" tumour microenvironment and chemoimmunotherapy combinations. mPDAC is well established as poorly immunogenic, and responses to immunotherapy alone are rare. The REVOLUTION platform trial evaluated gemcitabine/nab-paclitaxel plus ipilimumab with either nivolumab (cohort A) or hydroxychloroquine (cohort B) in untreated mPDAC. Cohort A achieved an ORR of 33% and a 12-month OS rate of 65.5% (95% CI 35.7%–84.0%), with higher baseline PD-1⁺CD39⁺ central memory CD4 T cells associated with prolonged survival; cohort B achieved an ORR of 40% and a 12-month OS rate of 53.9% (95% CI 24.3%–76.3%), though hydroxychloroquine-related tolerability issues contributed to early discontinuations. Grade 3–4 treatment-related adverse events occurred in 60% and 53% of patients in cohorts A and B, respectively.

• KRAS wild-type and molecularly defined subpopulations. KRAS wild-type mPDAC — representing approximately 19% of cases — harbours a distinct genomic landscape enriched for targetable alterations including BRAF, EGFR, FGFR, MSI-H/dMMR, HER2/ERBB2 amplification, BRCA1/2 and other HRDs, and gene fusions such as ALK, NTRK, and NRG1. A systematic review of 21 studies identified these as the most frequent actionable alterations in this subgroup, representing a population for whom standard chemotherapy backbones are unlikely to be optimal and precision-matched targeted therapy is an active area of development.

• Patients with ascites and advanced disease burden. mPC patients who develop ascites represent a particularly high-need population with very limited survival. A retrospective analysis of 117 mPC patients with ascites reported a median OS after ascites diagnosis of only 27.4 days. Liver metastases (HR 2.07), peritoneal carcinomatosis (HR 1.74), and portal vein obstruction (HR 2.52) were independently associated with impaired OS, while continuation of systemic therapy after ascites diagnosis was independently associated with longer OS (median 62 days vs. 16 days with best supportive care), highlighting the need for prospective trials incorporating quality-of-life assessment in this population.

• Novel targeted approaches beyond chemotherapy. For patients with mPDAC progressing on or ineligible for standard regimens, emerging strategies are being evaluated across multiple molecular targets. These include direct KRAS-targeted therapies, KRAS inhibitor combinations with immune checkpoint blockade, PARP inhibitors, CDK4/6 inhibitors and autophagy modulators, as well as NRG1 fusions, NTRK/ROS1 fusions, RET alterations, EGFR and Claudin18.2 inhibitors, and adoptive cell therapies (CAR-T, TCR, TIL) and cancer vaccines — reflecting the breadth of unmet need in a disease where durable responses to any single modality remain elusive.

Daraxonrasib's Position in the Pancreatic Cancer Pipeline

The knowledge base does not have sufficient information to answer this question.

The Evolving Treatment Landscape for Metastatic Pancreatic Adenocarcinoma

The NAPOLI 3 phase III randomised trial marked a significant inflection point in first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), demonstrating that NALIRIFOX (liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m²) achieved a median overall survival of 11.1 months versus 9.2 months with nab-paclitaxel and gemcitabine (hazard ratio 0.83; 95% CI 0.70–0.99; p=0.036) across 770 patients at 187 sites in 18 countries. A subsequent subgroup analysis of NAPOLI 3 confirmed that this survival benefit was preserved in patients aged ≥70 years — with median OS of 10.0 months and median PFS of 7.3 months in that cohort — and without signals of increased treatment-related toxicity compared with younger patients, supporting consideration of NALIRIFOX as a first-line triplet option in older but fit patients. A Bayesian network meta-analysis incorporating 79 randomised controlled trials (22,168 patients) further contextualised these findings, identifying NALIRIFOX (HR 0.56, 95% credible interval 0.45–0.70 for OS versus gemcitabine) and FOLFIRINOX (HR 0.66, 95% credible interval 0.56–0.78) as preferred regimens for patients able to tolerate them, with gemcitabine plus nab-paclitaxel remaining a viable alternative for those unfit for triplet therapy.

Real-world registry data have added nuance to the head-to-head question between FOLFIRINOX and gemcitabine/nab-paclitaxel. The prospective Australasian PURPLE registry (n=615 receiving palliative-intent chemotherapy) reported comparable median OS between first-line gemcitabine/nab-paclitaxel (11.3 months, n=376) and FOLFIRINOX (12.3 months, n=73; P=0.37), despite FOLFIRINOX recipients being younger, fitter, and more likely to have localised disease. Critically, 38% of patients proceeded to second-line chemotherapy, which was associated with substantially longer median OS compared with first-line treatment alone (17.4 versus 8.2 months; P<0.001). Among those receiving second-line therapy, median progression-free survival was longer following prior FOLFIRINOX than prior gemcitabine/nab-paclitaxel (5.2 versus 2.9 months; P=0.03), even though median OS did not differ significantly (17.3 versus 15.9 months; P=0.92). A multicenter retrospective analysis further characterised second-line nab-paclitaxel plus gemcitabine after FOLFIRINOX progression, reporting a median OS of 9.8 months (95% CI 8.9–10.6) and median PFS of 4.6 months (95% CI 3.7–5.5) from the start of second-line therapy, with a disease control rate of 73.6% and no treatment-related mortality.

Beyond cytotoxic sequencing, the emergence of molecularly targeted strategies represents the most substantive paradigm shift in mPDAC management. A synthesis of phase I–II trial data through April 2025 demonstrated that actionable alterations — present in a minority of patients but identifiable through comprehensive next-generation sequencing — can yield outcomes meeting or exceeding the NAPOLI-1 benchmark of 6.2 months median OS and 3.1 months PFS. Objective response rates of 33% with adagrasib in KRAS G12C PDAC, 22% with olaparib maintenance in germline BRCA1/2 cancers, and over 50% with RET or NTRK inhibitors in fusion-positive disease have been reported, alongside an overall response rate of 42% with zenocutuzumab in NRG1 fusion-positive tumours and durable benefit with pembrolizumab in the 1–3% of MSI-H/dMMR cases. The GABRINOX-2 phase II trial is additionally evaluating a sequential strategy of gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone in 162 patients with metastatic pancreatic cancer, with circulating tumour DNA and mRNA signature analyses embedded to identify predictive biomarkers — reflecting the field's broader movement toward precision-oncology integration alongside optimised cytotoxic sequencing.

EMA's Latest: Advancing Precision Across Key Therapeutic Areas

The recent positive opinions from the EMA's CHMP represent a significant stride forward in addressing critical unmet medical needs across oncology, metabolic health, and rare diseases. These recommendations underscore a growing trend towards highly targeted and patient-centric therapeutic innovations.

For patients battling metastatic pancreatic adenocarcinoma, the recommendation for Rasonque (daraxonrasib) is nothing short of a breakthrough. Pancreatic cancer has long been considered one of the most formidable challenges in oncology, with the oncogenic KRAS mutation, present in the vast majority of cases, historically deemed 'undruggable.' Daraxonrasib, as a multi-selective RAS(ON) inhibitor, directly targets this elusive pathway, offering a new lifeline where options were scarce. Clinical data indicating a near doubling of overall survival compared to chemotherapy in previously treated patients highlights its potential to fundamentally reshape treatment paradigms, moving towards a precision oncology approach. However, the complex biology of RAS-driven cancers means that resistance mechanisms will likely emerge, necessitating continued research into combination therapies and comprehensive molecular profiling to guide treatment selection.

In the rapidly expanding landscape of metabolic disorders, Foundayo (orforglipron) stands out as a novel oral glucagon-like peptide-1 (GLP-1) receptor agonist. Its small-molecule, non-peptide nature offers a distinct advantage in convenience, eliminating the food and water restrictions associated with some existing oral GLP-1 RAs. This could significantly enhance patient adherence and broaden access to effective weight management and type 2 diabetes control. While its efficacy in reducing body weight and HbA1c is robust, clinicians will need to manage the class-specific gastrointestinal side effects, particularly during dose escalation, and monitor for potential signals like mild pancreatitis or heart rate changes.

Finally, Yuviwel (navepegritide) brings a much-needed targeted therapy to children with achondroplasia. This genetic disorder, caused by an overactive FGFR3 receptor, has historically been managed with supportive care or invasive surgeries offering limited benefits. Navepegritide, by antagonizing the downstream MAPK pathway, directly addresses the underlying molecular defect, leading to improved annualized growth velocity and other health benefits. This represents a paradigm shift from symptomatic management to disease modification. While early safety data are favorable, long-term studies are crucial to understand its full impact on the various comorbidities associated with achondroplasia and the sustained durability of its benefits.